[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease

J Booij, G Tissingh, G J Boer, J D Speelman, J C Stoof, A G Janssen, E C Wolters, E A van Royen, J Booij, G Tissingh, G J Boer, J D Speelman, J C Stoof, A G Janssen, E C Wolters, E A van Royen

Abstract

Objectives: The main neuropathological feature in Parkinson's disease is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine (DA) transporters in the striatum. [123I]beta-CIT single photon emission computed tomography (SPECT) studies have demonstrated this loss of striatal DA transporter content in Parkinson's disease in vivo. However, studies with this radioligand also showed that an adequate imaging of the striatal DA transporter content could only be performed on the day after the injection of radioligand, which is not convenient for outpatient evaluations. Recently, a new radioligand [123I]FP-CIT, with faster kinetics than beta-CIT, became available for imaging of the DA transporter with SPECT, and the applicability of this ligand was tested in patients with early and advanced Parkinson's disease, using a one day protocol.

Methods: [123I]FP-CIT SPECT was performed in six patients with early and 12 patients with advanced Parkinson's disease, and in six age matched healthy volunteers.

Results: Compared with an age matched control group striatal [123I]FP-CIT uptake in patients with Parkinson's disease was decreased, and this result was measurable three hours after injection of the radioligand. In the Parkinson's disease group the uptake in the putamen was reduced more than in the caudate nucleus. The contralateral striatal uptake of [123I]FP-CIT was significantly lower than the ipsilateral striatal uptake in the Parkinson's disease group. Specific to non-specific striatal uptake ratios correlated with the Hoehn and Yahr stage. A subgroup of patients with early Parkinson's disease also showed significantly lower uptake in the putamen and lower putamen:caudate ratios than controls.

Conclusion: [123I]FP-CIT SPECT allows a significant discrimination between patients with Parkinson's disease and age matched controls with a one day protocol, which will be to great advantage in outpatient evaluations.

References

    1. Neurology. 1967 May;17(5):427-42
    1. J Neurol Sci. 1973 Dec;20(4):415-55
    1. Adv Neurol. 1987;45:19-34
    1. N Engl J Med. 1988 Apr 7;318(14):876-80
    1. Acta Neurol Scand. 1988 Mar;77(3):192-201
    1. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
    1. J Neurochem. 1989 Nov;53(5):1400-4
    1. Ann Neurol. 1989 Dec;26(6):766-70
    1. Neurobiol Aging. 1989 Nov-Dec;10(6):661-4
    1. Trends Neurosci. 1990 Jul;13(7):290-6
    1. Acta Psychiatr Scand Suppl. 1990;358:67-71
    1. Ann Neurol. 1990 Oct;28(4):547-55
    1. Arch Neurol. 1990 Dec;47(12):1290-8
    1. Synapse. 1991 Sep;9(1):43-9
    1. Mov Disord. 1992;7(1):2-13
    1. Eur J Pharmacol. 1992 May 27;216(1):109-12
    1. J Neurol Sci. 1993 Mar;115(1):1-17
    1. Synapse. 1993 Apr;13(4):295-309
    1. Ann Neurol. 1993 Sep;34(3):423-31
    1. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11965-9
    1. J Neural Transm Gen Sect. 1993;94(2):137-46
    1. J Med Chem. 1994 May 27;37(11):1558-61
    1. Synapse. 1994 Jun;17(2):115-24
    1. J Cereb Blood Flow Metab. 1994 Nov;14(6):982-94
    1. Nucl Med Biol. 1995 Feb;22(2):211-9
    1. J Nucl Med. 1995 Jul;36(7):1175-81
    1. Synapse. 1995 Apr;19(4):297-300
    1. J Neural Transm Park Dis Dement Sect. 1995;9(1):55-71
    1. Eur J Nucl Med. 1995 Apr;22(4):356-60
    1. Ann Neurol. 1995 Oct;38(4):589-98
    1. J Neurol Neurosurg Psychiatry. 1995 Dec;59(6):597-600
    1. Synapse. 1995 Oct;21(2):97-103
    1. Nucl Med Biol. 1995 Oct;22(7):905-13
    1. Neurology. 1996 Jan;46(1):231-7
    1. J Med Chem. 1996 Jan 19;39(2):543-8
    1. J Nucl Med. 1996 Jul;37(7):1129-33

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel